DeutschNewstral
Article
bizjournals.com on 2015-05-06 13:23
Cambridge rare disease biotech Synageva to be acquired for $8.4B
Related news
- Cambridge biotech with rare blood disease drug secures $59Mbizjournals.com
- Merck takes stake in small Cambridge rare disease biotech, lifting sharesbizjournals.com
- Cambridge biotech VC firm Clarus acquired by Blackstonebizjournals.com
Retired Cambridge minister taking part in rare disease trialscambridgeindependent.co.uk
Alexion Pharma to pay $8.4B for Synageva BioPharmaseattletimes.com- Cambridge biotech Acceleron to be acquired by Merck for $11.5Bbizjournals.com
- Cambridge biotech startup grabs $65M to tackle liver diseasebizjournals.com
- For Rare Disease Day, Cambridge firm launches podcastbizjournals.com
- Everything you need to know about the $8.4B acquisition of Synagevabizjournals.com
- Cambridge biotech delivers coronavirus vaccinebizjournals.com
- Cambridge startup Weathermob acquiredbizjournals.com
Alexion-Synageva Deal Shows Lure of Rare-Disease Drugswsj.com- Cambridge biotech plans manufacturing hub in Marylandbizjournals.com
- Cambridge biotech Werewolf gets $72M funding roundbizjournals.com
- Cambridge BioMarketing acquired for $33 millionbizjournals.com
- Biotech startup expands from Cambridge to Watertownbizjournals.com
- Cambridge biotech to return its PPP loanbizjournals.com
- Cambridge biotech relocates to West Coastbizjournals.com
- Kraft Group participates in $30M funding for Cambridge biotechbizjournals.com
- Former head of Millennium to head Cambridge biotech startup Mersanabizjournals.com